Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma

Basit Öğe Kaydı
dc.contributor.authorAbakay, A.
dc.contributor.authorKomek, H.
dc.contributor.authorAbakay, O.
dc.contributor.authorPalanci, Y.
dc.contributor.authorEkici, F.
dc.contributor.authorTekbas, G.
dc.contributor.authorTanrikulu, A. C.
dc.date.accessioned2024-04-24T17:37:55Z
dc.date.available2024-04-24T17:37:55Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND AND OBJECTIVES: Malignant pleural mesothelioma (MPM) is a fatal malignancy. Radiological imaging is necessary for the diagnosis, staging, and clinical management of patients with MPM. The 18 fluorodeoxyglucose positron emission tomography (18 FDG-PET) scan has proven useful in preoperative staging and as a prognostic tool in MPM. We aimed to investigate the relationship between the pre-treatment 18 FDG PET/CT results, together with other known clinical parameters, and the survival of patients with MPM in our region. PATIENTS AND METHODS: A retrospective analysis was performed on the data of 177 patients with MPM between April 2007 and April 2011. Pretreatment 18 FDG PET/CT scans were done on all patients. Survival time was calculated by the Kaplan-Meier method. RESULTS: The mean age was 55.40 years. There were 56% male patients and 44% female patients. The mean survival time was 11 months from time of diagnosis. According to multivariate analysis results, being of male gender increased the poor prognosis 5.30 times, a Karnofsky performance score (KPS) < 60 increased a poor prognosis 2.18 times, being on best supportive care increased a poor prognosis 25.40 times, the stage III-IV increased a poor prognosis 11.13 times, and a level of maximum standardized uptake value (SUVmax) > 5 increased a poor prognosis 4.34 times. CONCLUSIONS: MPM remains a fatal prognosis. Significant predictors of survival include KPS, stage of disease, gender, treatment regimen and level of SUVmax. An understanding of the importance of these markers for MPM prognosis should allow targeted treatments to be developed.en_US
dc.identifier.endpage1241en_US
dc.identifier.issn1128-3602
dc.identifier.issue9en_US
dc.identifier.pmid23690193
dc.identifier.scopus2-s2.0-84878544282
dc.identifier.scopusqualityQ2
dc.identifier.startpage1233en_US
dc.identifier.urihttps://hdl.handle.net/11468/21246
dc.identifier.volume17en_US
dc.identifier.wosWOS:000319518300013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMesotheliomaen_US
dc.subjectPoor Prognosisen_US
dc.subjectFdg-Peten_US
dc.subjectSuvmaxen_US
dc.titleRelationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesotheliomaen_US
dc.titleRelationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu